[关键词]
[摘要]
目的 观察注射用丹参多酚酸治疗急性脑梗死临床疗效。方法 选择2017年9月—2018年7月哈尔滨市第二医院神经内科收治的急性脑梗死患者86例为研究对象。使用统计软件随机数字法将患者分为对照组和观察组,每组各43例。对照组实施临床常规治疗,观察组在对照组的基础上给予注射用丹参多酚酸,将其溶于250 mL生理盐水中进行静脉滴注给药,1次/d。两组均持续用药治疗14 d。分别比较两组患者治疗前后临床疗效、美国国立卫生研究院卒中量表(NIHSS)评分及日常生活能力量表巴氏指数(BI)评分。结果 治疗后,观察组临床疗效为79.07%,显著高于对照组的53.49%(P<0.05)。治疗后,对照组与观察组患者NIHSS评分与治疗前比较显著降低,BI评分与治疗前比较升高,差异有统计学意义(P<0.05);观察组患者NIHSS评分和BI评分显著优于对照组,差异具有统计学意义(P<0.05)。结论 注射用丹参多酚酸能改善急性脑梗死患者脑血管的血流动力学,有效改善缺血等症状,临床疗效确切,具有一定的临床推广价值。
[Key word]
[Abstract]
Objective To observe the clinical efficacy of Salvianolate for injection in treatment of acute cerebral infarction. Methods Patients (86 cases) with acute cerebral infarction from September 2017 to July 2018 in the department of neurology, Harbin Second Hospital were randomly divided into control group and observation group, 43 cases of patients in each group. Patients in the control group were received routine clinical treatment, and patients in the observation group were iv administered with Salvianolate for injection on the basis of the control group, which was dissolved in 250 mL normal saline for once daily. Both groups were treated for 14 d. The clinical efficacy, NIHSS score, and BI score of the two groups were compared before and after treatment. Results After treatment, the clinical efficacy in the observation group was 79.07%, which was significantly higher than 53.49% in the control group (P < 0.05). After treatment, the NIHSS score of the control group and the observation group were significantly decreased compared with that before treatment, and the BI score were increased, with statistically significant difference (P < 0.05). The NIHSS and BI score of the observation group was significantly better than that of the control group, and the difference was statistically significant (P < 0.05). Conclusion Salvianolate for injection can improve the hemodynamics of cerebral vessels in patients with acute cerebral infarction, effectively improve the symptoms of ischemia and other symptoms, clinical efficacy is accurate, which has a certain clinical promotion value.
[中图分类号]
R969.4
[基金项目]